Jakub Tolar, M.D., Ph.D.
Tulloch Chair in Stem Cell Biology, Genetics and Genomics; Director, Stem Cell Institute
Professor, Department of Pediatric Blood & Marrow Transplantation
“In order to cure the incurable, we need more than compassion – we need knowledge. That knowledge comes from research."
Dr. Tolar focuses on using hematopoietic stem cell transplant as a treatment for rare genetic disorders including Hurler syndrome, dyskeratosis congenital and has achieved international recognition for his work in caring for patients with recessive dystrophic epidermolysis bullosa.
Medical School: Charles University, Prague, Czech Republic
Doctor of Philosphy (PhD): University of Minnesota (Molecular, Cellular, Developmental Biology and Genetics)
Residency: University of Minnesota (Pediatrics)
Fellowship: University of Minnesota (Hematology/Oncology and Blood and Marrow Transplantation)
Dr. Tolar is focused on integrating clinical observation, molecular biology, immunology, and laboratory research in studying and treating children with serious illness including cancer and other devastating genetic disorders.
Dr. Tolar is currently working on treatment protocols using hematopoietic stem cell transplant as a treatment for Hurler syndrome, Fanconi anemia, recessive dystrophic epidermolysis bullosa, dyskeratosis congenita, and severe aplastic anemia.
A Selection of Recent Awards and Publications
On Medawar's 'Actively acquired tolerance of foreign cells'. Tolar J, Tolarova S, McGrath JA. Exp Dermatol. 2014 Feb;23(2):97-8. doi: 10.1111/exd.12227.
Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. Tolar J, McGrath JA, Xia L, Riddle MJ, Lees CJ, Eide C, Keene DR, Liu L, Osborn MJ, Lund TC, Blazar BR, Wagner JE. J Invest Dermatol. 2014 May;134(5):1246-54. doi: 10.1038/jid.2013.523. Epub 2013 Dec 6.
Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix. Tolar J, Wagner JE. Lancet. 2013 Oct 5;382(9899):1214-23. doi: 10.1016/S0140-6736(13)61897-8. Review.
Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Aoyama K, Saha A, Tolar J, Riddle MJ, Veenstra RG, Taylor PA, Blomhoff R, Panoskaltsis-Mortari A, Klebanoff CA, Socié G, Munn DH, Murphy WJ, Serody JS, Fulton LM, Teshima T, Chandraratna RA, Dmitrovsky E, Guo Y, Noelle RJ, Blazar BR. Blood. 2013 Sep 19;122(12):2125-34. doi: 10.1182/blood-2012-11-470252. Epub 2013 Jun 27.
Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa. John E. Wagner, M.D., Akemi Ishida-Yamamoto, M.D., Ph.D., John A. McGrath, M.D., Maria Hordinsky, M.D., Douglas R. Keene, B.S., David T. Woodley, M.D., Mei Chen, Ph.D., Megan J. Riddle, B.A., Mark J. Osborn, Ph.D., Troy Lund, M.D., Ph.D., Michelle Dolan, M.D., Bruce R. Blazar, M.D., and Jakub Tolar, M.D., Ph.D. N Engl J Med 2010; 363:629-639August 12, 2010DOI: 10.1056/NEJMoa0910501
Click here to see a complete list of Dr. Tolar’s work which has been published by academic and research journals.
Best Doctors in America® (2011, 2012, 2013)
Mpls.St. Paul Top Doctors, 2012
Albert D. and Eva J. Corniea Chair, 2011-2016